Explore Our Publications
Entrada’s commitment to publications & transparency
Entrada is committed to publishing the results of our sponsored research in a transparent, scientifically accurate, and timely manner. Entrada will apply high ethical standards to our publications and presentations and will adhere to recognized industry guidance such as International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals and International Society for Medical Publication Professionals (ISMPP) Good Publication Practice for Communicating Company Sponsored Medical Research.
Past Presentations
-
Development of the Endosomal Escape Vehicle (EEV™) Platform to Enhance the Intracellular Delivery of Oligonucleotides
- By: Leo Ziqing Qian, PhD, Co-Founder & Vice President, Discovery Research, Entrada Therapeutics
- At: Gordon Research Conference: Exploring Peptides as Natural and Unnatural Scaffolds for Discovery
- On: February 11, 2024
DownloadFebruary 11, 2024 -
Utility of a 3D Engineered Skeletal Muscle Organoid System to Assess Exon Skipping, Dystrophin Protein Restoration and Functional Improvement in a Human DMD Cell Model
- By: Nelsa Estrella, PhD, Associate Director, Neuromuscular, Entrada Therapeutics
- At: CELL BIO 2023
- On: December 5, 2023
DownloadDecember 5, 2023 -
Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugates Produce Exon Skipping and Dystrophin Production in Preclinical Models of Duchenne Muscular Dystrophy
- By: Mahasweta Girgenrath, PhD, Vice President Neuromuscular, Entrada Therapeutics
- At: Frontiers in Myogenesis Conference 2023
- On: November 10, 2023
DownloadNovember 10, 2023 -
Utility of a 3D Engineered Skeletal Muscle Organoid System to Assess Exon Skipping and Dystrophin Protein Restoration in a Human DMD Cell Model
- By: Nelsa Estrella, PhD, Associate Director, Neuromuscular, Entrada Therapeutics
- At: Frontiers in Myogenesis Conference 2023
- On: November 6, 2023
DownloadNovember 6, 2023 -
Exon Skipping and Dystrophin Production with ENTR-601-45, a Novel EEV-Conjugated, Exon 45 Skip Amenable PMO in Preclinical Models of DMD
- By: Xiang Li, PhD, Director, Discovery Research, Entrada Therapeutics
- At: 19th Annual Meeting of the Oligonucleotide Therapeutics Society
- On: October 22, 2023
DownloadOctober 22, 2023 -
The Endosomal Escape Vehicle (EEV™) Platform Enhances the Delivery of Oligonucleotides to Skeletal and Cardiac Muscle
- By: Mahboubeh Kheirabadi, PhD, Director, Discovery Chemistry, Entrada Therapeutics
- At: 19th Annual Meeting of the Oligonucleotide Therapeutics Society
- On: October 22, 2023
DownloadOctober 22, 2023